<?xml version="1.0" encoding="utf-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:og="http://ogp.me/ns#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:schema="http://schema.org/" xmlns:sioc="http://rdfs.org/sioc/ns#" xmlns:sioct="http://rdfs.org/sioc/types#" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" version="2.0" xml:base="http://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/medwatch/rss.xml">
  <channel>
    <title>MedWatch Safety Alerts RSS Feed</title>
    <link>http://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/medwatch/rss.xml</link>
    <description/>
    <language>en</language>
    
    <item>
  <title>CBER FY 2019 Recall Postings</title>
  <link>http://www.fda.gov/vaccines-blood-biologics/recalls-biologics/cber-fy-2019-recall-postings</link>
  <description>Listing of CBER FY 2019 Recall Postings</description>
  <pubDate>Wed, 02 Oct 2019 07:15:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/vaccines-blood-biologics/recalls-biologics/cber-fy-2019-recall-postings</guid>
    </item>
<item>
  <title>CBER FY 2018 Recall Postings</title>
  <link>http://www.fda.gov/vaccines-blood-biologics/recalls-biologics/cber-fy-2018-recall-postings</link>
  <description>List of CBER FY 2018 Recall Postings.</description>
  <pubDate>Wed, 02 Oct 2019 07:15:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/vaccines-blood-biologics/recalls-biologics/cber-fy-2018-recall-postings</guid>
    </item>
<item>
  <title>2019 Safety Communications</title>
  <link>http://www.fda.gov/medical-devices/safety-communications/2019-safety-communications</link>
  <description>The FDA posts Medical Device Safety Communications to describe the FDA's current analysis of an issue and contain specific regulatory approaches and clinical recommendations for patient management.</description>
  <pubDate>Tue, 01 Oct 2019 10:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/medical-devices/safety-communications/2019-safety-communications</guid>
    </item>
<item>
  <title>URGENT/11 Cybersecurity Vulnerabilities in a Widely-Used Third-Party Software Component May Introduce Risks During Use of Certain Medical Devices: FDA Safety Communication</title>
  <link>http://www.fda.gov/medical-devices/safety-communications/urgent11-cybersecurity-vulnerabilities-widely-used-third-party-software-component-may-introduce</link>
  <description>URGENT/11 Cybersecurity Vulnerabilities in a Widely-Used Third-Party Software Component May Introduce Risks During Use of Certain Medical Devices: FDA Safety Communication</description>
  <pubDate>Tue, 01 Oct 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/medical-devices/safety-communications/urgent11-cybersecurity-vulnerabilities-widely-used-third-party-software-component-may-introduce</guid>
    </item>
<item>
  <title>Mavidon Issues Voluntary Worldwide Recall of LemonPrep® Tubes and Single Use Cups</title>
  <link>http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/mavidon-issues-voluntary-worldwide-recall-lemonprepr-tubes-and-single-use-cups</link>
  <description>Mavidon is voluntarily recalling 21 lots of LemonPrep® 4 ounce tubes and single use cups to user level. These products have been found to be contaminated with Burkholderia cepacia. The specific lots are listed below:</description>
  <pubDate>Thu, 26 Sep 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/mavidon-issues-voluntary-worldwide-recall-lemonprepr-tubes-and-single-use-cups</guid>
    </item>
<item>
  <title>Apotex Corp. Issues Voluntary Nationwide Recall of Ranitidine Tablets 75mg and 150mg (All pack sizes and Formats) due to the potential for Detection of an Amount of Unexpected Impurity,N-nitrosodimethylamine (NDMA) Impurity in the product</title>
  <link>http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/apotex-corp-issues-voluntary-nationwide-recall-ranitidine-tablets-75mg-and-150mg-all-pack-sizes-and</link>
  <description>Apotex Corp. is voluntarily, on a precautionary basis, recalling Ranitidine Tablets 75mg and 150mg (All pack sizes and Formats) to the Retail level. Apotex has learned from the U.S. Food and Drug Administration and other Global regulators that some ranitidine medicines including brand and generic fo</description>
  <pubDate>Wed, 25 Sep 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/apotex-corp-issues-voluntary-nationwide-recall-ranitidine-tablets-75mg-and-150mg-all-pack-sizes-and</guid>
    </item>
<item>
  <title>Sandoz Inc. Issues Voluntary Recall of Ranitidine Hydrochloride Capsules 150mg and 300mg  Due to An Elevated Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA), in the Product</title>
  <link>http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sandoz-inc-issues-voluntary-recall-ranitidine-hydrochloride-capsules-150mg-and-300mg-due-elevated</link>
  <description>–  Sandoz Inc. is voluntarily recalling all quantities and lots within expiry of Ranitidine Hydrochloride Capsules in the US to the consumer level because of confirmed contamination with N-Nitrosodimethylamine (NDMA) above levels established by the FDA in batches of Sandoz Ranitidine Hydrochloride C</description>
  <pubDate>Mon, 23 Sep 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sandoz-inc-issues-voluntary-recall-ranitidine-hydrochloride-capsules-150mg-and-300mg-due-elevated</guid>
    </item>
<item>
  <title>Updated: Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium / Hydrochlorothiazide Tablets, USP</title>
  <link>http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium-0</link>
  <description>Torrent Pharmaceuticals Limited is expanding its recall for Losartan Potassium Tablets USP and Losartan Potassium/hydrochlorothiazide tablets, USP, to the consumer level due to the detection of trace amounts of an unexpected impurity.</description>
  <pubDate>Thu, 19 Sep 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium-0</guid>
    </item>
<item>
  <title>Teleflex Medical Recalls the Hudson RCI Sheridan and Sheridan Endotracheal Tubes Due to Risk of the Sheridan Connector Disconnecting from the Breathing Circuit</title>
  <link>http://www.fda.gov/medical-devices/medical-device-recalls/teleflex-medical-recalls-hudson-rci-sheridan-and-sheridan-endotracheal-tubes-due-risk-sheridan</link>
  <description>FDA has classified the voluntary action as a Class I recall for the Teleflex Medical Recalls the Hudson RCI Sheridan and Sheridan Endotracheal Tubes Due to Risk of the Sheridan Connector Disconnecting from the Breathing Circuit</description>
  <pubDate>Tue, 17 Sep 2019 12:45:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/medical-devices/medical-device-recalls/teleflex-medical-recalls-hudson-rci-sheridan-and-sheridan-endotracheal-tubes-due-risk-sheridan</guid>
    </item>
<item>
  <title>Fitoterapia USA Inc. Issues Voluntary Nationwide Recall of MERO MACHO ARTIFICIAL PASSION FRUIT FLAVORED VITAMIN C LIQUID SUPPLEMENT Due to Presence of Active Ingredient Tadalafil</title>
  <link>http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/fitoterapia-usa-inc-issues-voluntary-nationwide-recall-mero-macho-artificial-passion-fruit-flavored</link>
  <description>Fitoterapia USA Inc., is voluntarily recalling 19,000 bottles of MACHO ARTIFICIAL PASSION FRUIT FLAVORED VITAMIN C LIQUID SUPPLEMENT, liquid dietary supplement to the consumer level. FDA analysis has found the product to be tainted with Tadalafil. Tadalafil is an active ingredient in a FDA- approved</description>
  <pubDate>Mon, 16 Sep 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/fitoterapia-usa-inc-issues-voluntary-nationwide-recall-mero-macho-artificial-passion-fruit-flavored</guid>
    </item>
<item>
  <title>2019 Medical Device Recalls</title>
  <link>http://www.fda.gov/medical-devices/medical-device-recalls/2019-medical-device-recalls</link>
  <description>The list below contains recalls that were issued in 2019.</description>
  <pubDate>Thu, 12 Sep 2019 10:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/medical-devices/medical-device-recalls/2019-medical-device-recalls</guid>
    </item>
<item>
  <title>Darmerica LLC Issues Voluntary Nationwide Recall of Quinacrine Dihydrochloride Due to A Labeling Error</title>
  <link>http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/darmerica-llc-issues-voluntary-nationwide-recall-quinacrine-dihydrochloride-due-labeling-error</link>
  <description> Darmerica LLC is voluntarily recalling two lots, DR4654A and DL4654A, of Quinacrine Dihydrochloride, bulk API powder packaged in Amber HDPE Bottles to the consumer level. This product is being recalled due to a label mix-up. Product intended for further compounding use by pharmacies labeled as Quin</description>
  <pubDate>Thu, 12 Sep 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/darmerica-llc-issues-voluntary-nationwide-recall-quinacrine-dihydrochloride-due-labeling-error</guid>
    </item>
<item>
  <title>KRS Global Biotechnology, Inc.  Issues Voluntary Nationwide Recall of All Human and Animal Sterile Drug Products Due to Lack of Assurance of Sterility</title>
  <link>http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/krs-global-biotechnology-inc-issues-voluntary-nationwide-recall-all-human-and-animal-sterile-drug</link>
  <description>KRS Global Biotechnology, Inc. is voluntarily recalling all lots of unexpired human and animal drugs intended to be sterile to the consumer level.    The products are being recalled due to lack of assurance of sterility.</description>
  <pubDate>Thu, 12 Sep 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/krs-global-biotechnology-inc-issues-voluntary-nationwide-recall-all-human-and-animal-sterile-drug</guid>
    </item>
<item>
  <title>Allergan Recalls Natrelle Biocell Textured Breast Implants Due to Risk of BIA-ALCL Cancer</title>
  <link>http://www.fda.gov/medical-devices/medical-device-recalls/allergan-recalls-natrelle-biocell-textured-breast-implants-due-risk-bia-alcl-cancer</link>
  <description>Allergan Recalls Natrelle Biocell Textured Breast Implants Due to Risk of BIA-ALCL Cancer</description>
  <pubDate>Thu, 12 Sep 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/medical-devices/medical-device-recalls/allergan-recalls-natrelle-biocell-textured-breast-implants-due-risk-bia-alcl-cancer</guid>
    </item>
<item>
  <title>The Metrix Company of Dubuque, Iowa is Recalling Specific Lots of the Empty IV Flexible Containers (Bag) Marketed Under the Metrix Secure EVA Dual Chamber and Baxter ExactaMix Names, Due to the Potential for Leaking of the IV Bag at the Chamber Divider Rod</title>
  <link>http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/metrix-company-dubuque-iowa-recalling-specific-lots-empty-iv-flexible-containers-bag-marketed-under</link>
  <description>The Metrix Company of Dubuque, Iowa is recalling specific lots of the empty IV flexible containers (bag) marketed under the Metrix Secure EVA Dual Chamber and Baxter ExactaMix names, due to the potential for leaking of the IV bag at the chamber divider rod, which could result in a serious infection </description>
  <pubDate>Tue, 10 Sep 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/metrix-company-dubuque-iowa-recalling-specific-lots-empty-iv-flexible-containers-bag-marketed-under</guid>
    </item>
<item>
  <title>Certain Medtronic MiniMed Insulin Pumps Have Potential Cybersecurity Risks: FDA Safety Communication</title>
  <link>http://www.fda.gov/medical-devices/safety-communications/certain-medtronic-minimed-insulin-pumps-have-potential-cybersecurity-risks-fda-safety-communication</link>
  <description>Patients with diabetes using these models should switch their insulin pump to models that are better equipped to protect against these potential risks.</description>
  <pubDate>Mon, 09 Sep 2019 09:09:25 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/medical-devices/safety-communications/certain-medtronic-minimed-insulin-pumps-have-potential-cybersecurity-risks-fda-safety-communication</guid>
    </item>
<item>
  <title>Plastikon Healthcare Issues Voluntary Nationwide Recall of Milk of Magnesia Oral Suspension 2400 mg/30 mL due to Microbial Contamination</title>
  <link>http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/plastikon-healthcare-issues-voluntary-nationwide-recall-milk-magnesia-oral-suspension-2400-mg30-ml</link>
  <description>Plastikon Healthcare, LLC isvoluntarily recalling Milk of Magnesia 2400 mg/30 mL Oral Suspension, lots 19027D and 19027E, to the patient level. Plastikon Healthcare initiated this recall because these product lots did not meet Plastikon’s in-house microbiological specification for Total Aerobic Mic</description>
  <pubDate>Mon, 09 Sep 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/plastikon-healthcare-issues-voluntary-nationwide-recall-milk-magnesia-oral-suspension-2400-mg30-ml</guid>
    </item>
<item>
  <title>Hospira, Inc., Issues A Voluntary Nationwide Recall for one lot of BACTERIOSTATIC WATER for Injection, USP, due to a Potential Lack of Sterility Assurance</title>
  <link>http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/hospira-inc-issues-voluntary-nationwide-recall-one-lot-bacteriostatic-water-injection-usp-due</link>
  <description>Hospira, Inc., a Pfizer company, is voluntarily recalling BACTERIOSTATIC WATER for Injection, USP, 30 mL, multi-dose vial, lot W20308, to the Hospital/Retail level. Hospira initiated this recall due to lack of confirmation of sterilization for some vials from this lot.</description>
  <pubDate>Fri, 06 Sep 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/hospira-inc-issues-voluntary-nationwide-recall-one-lot-bacteriostatic-water-injection-usp-due</guid>
    </item>
<item>
  <title>Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate</title>
  <link>http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/takeda-issues-us-recall-natparar-parathyroid-hormone-injection-due-potential-rubber-particulate</link>
  <description>Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is issuing a US recall for all doses of NATPARA® (parathyroid hormone) for Injection (25 mcg, 50 mcg, 75 mcg, and 100 mcg). This recall is being conducted after discussions with the FDA and is effec</description>
  <pubDate>Thu, 05 Sep 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/takeda-issues-us-recall-natparar-parathyroid-hormone-injection-due-potential-rubber-particulate</guid>
    </item>
<item>
  <title>Pacifico National, Inc. dba AmEx Pharmacy Issues Voluntary Nationwide Recall for all Lots of Bevacizumab</title>
  <link>http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/pacifico-national-inc-dba-amex-pharmacy-issues-voluntary-nationwide-recall-all-lots-bevacizumab</link>
  <description>AmEx Pharmacy today announces a voluntary recall of all Lots of Bevacizumab 1.25mg/0.05mL 31G Injectable and all Lots of Bevacizumab 2.5mg/0.1ml Normject TB Injectable that are within expiry to the healthcare provider level. These lots are being recalled out of an abundance of caution following an F</description>
  <pubDate>Fri, 30 Aug 2019 00:00:00 EDT</pubDate>
    <dc:creator>FDA</dc:creator>
    <guid isPermaLink="true">http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/pacifico-national-inc-dba-amex-pharmacy-issues-voluntary-nationwide-recall-all-lots-bevacizumab</guid>
    </item>

  </channel>
</rss>
